Nokod Security to Host Capture the Flag Competition and Demonstrate Microsoft Power BI Vulnerability at OWASP Global AppSec EU 2025
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)-- Nokod Security, the security company for no-code application development, today announced it will host a no-code Capture the Flag (CTF) hacking competition in collaboration with OWASP at Global AppSec EU 2025 in Barcelona. In addition, Nokod Senior Security Researcher Uriya Elkayam will present a session that exposes data leakage vulnerabilities affecting Power BI reports.
Attendees can compete in a live event to uncover vulnerabilities in no-code apps that expose sensitive data. All players who successfully complete the challenge will be entered to win prizes, including a DJI NEO Mini Drone and 9 JBL GO 4 speakers.
Share
WHO: Nokod Security helps enterprises secure their no-code application development environments.
WHAT:
No-Code Capture the Flag (CTF) Competition
Security researchers will compete in a live event to uncover vulnerabilities in no-code apps that expose sensitive data. All players who successfully complete the challenge will be entered to win prizes, including a DJI NEO Mini Drone and 9 JBL GO 4 speakers.
Conference Session: To BI or Not to BI? Data Leakage Tragedies with Power BI Reports
In this session, Uriya Elkayam will demonstrate how a vulnerability in Microsoft Fabric (Power BI) can allow unauthorized data access via API manipulation, especially in publicly shared reports. He will present PBAnalyzer, an open-source tool developed by Nokod Security, which helps organizations identify data oversharing in widely shared Power BI reports. He will also unveil a new attack technique called DAX Injection, which exploits Power BI queries through Power Automate flows. This attack could potentially lead to external data leakage. The session will conclude with actionable steps for securing Power BI environments.
WHEN & WHERE:
No-Code CTF Competition
Live Event: Friday, May 30
10:00 am - 2:00 pm
Room: 118
Location: OWASP 2025 Global AppSec, Fira Barcelona Conference Center
Conference Session
To BI or Not to BI? Data Leakage Tragedies with Power BI Reports
Thursday, May 29, 2025, 3:30 pm – 4:15 pm CET
Room 113, Fira Barcelona Conference Center
HOW: To schedule a conversation with Nokod Security about no-code and BI platform security contact Marc Gendron at marc@mgpr.net or +1 617.877.7480.
About Nokod Security
Nokod Security is the security company for no-code application development. The Nokod Security Platform protects enterprises from risks introduced by no-code applications across Microsoft Power Platform, UiPath, Salesforce, ServiceNow, and more. Founded by cybersecurity veterans from Imperva and SecuredTouch (now Ping Identity), Nokod is backed by Acrew Capital, Meron Capital, and Flint Capital. Learn more at www.nokodsecurity.com or follow us on X and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase (MTP) – – Interim analysis follows evaluation of 50% of target enrollment in study; completion of enrollment anticipated in 2H25 with topline data by year end – – Selected for late-breaking podium presentation today at 1:15 PM CT – TEL AVIV, Israel, May 31, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced updated interim results from ENLIGHTED, the Company's ongoing Phase 3 study of Padeliporfin VTP treatment in patients with low-grade upper tract urothelial cancer (UTUC). These data will be presented in a late-breaking podium session at the at the American Society of Clinical Oncology Annual Meeting taking place May 30 – June 3, 2025, in Chicago, Illinois. 'We are pleased to share this interim analysis, now capturing 50% of target enrollment in ENLIGHTED, which continues to reinforce Padeliporfin VTP's best-in-class potential in low-grade UTUC,' said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. 'We believe the emerging profile – a non-invasive treatment option delivering robust and sustained surgery-like efficacy, but without the associated risk of organ injury or loss – presents clear advantages over the standard of care. We are urgently progressing development to bring underserved UTUC patients this paradigm-shifting treatment and look forward to announcing potentially registrational topline data, including a view into durability, in UTUC within the year.' Key results from the interim analysis of the Phase 3 ENLIGHTED study of Padeliporfin VTP: As of November 5, 2024, the data cut-off for the poster presentation at ASCO, 43 patients had begun treatment, of which 37 had completed ITP and were evaluable for efficacy. Clinical Profile: 27 of the 37 (73%) response-evaluable patients achieved a CR at the end of ITP. 5 of the 37 (13.5%) response-evaluable patients achieved a partial response (PR) at the end of ITP. Safety and Tolerability Profile: Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the Phase 1 study and previously announced preliminary Phase 3 results. Adverse events (AEs): the majority of treatment-emergent adverse events (TEAEs) were mild or moderate and were primarily URS related, resolving within a few days. The most common Grade 3 serious adverse events related to VTP treatment were hematuria, dysuria and flank pain, which resolved within a few days. No TEAEs of special interest were reported and no TEAE led to discontinuation of the study treatment. ImPact continues to recruit for the ENLIGHTED study and expects to complete enrollment in the second half of 2025. The company anticipates the presentation of topline ENLIGHTED data in 2025. Podium Presentation Details: Poster Title: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC): ENLIGHTED phase 3 studyPresenter: Vitaly Margulis, Professor of Urologic Oncology, University of Texas Southwestern Medical CenterPoster Number: LBA4513Session Title: Bladder Cancer: Upper Tract Transitional Cell CarcinomaSession Date & Time: May 31, 2025, 1:15 PM CT About ENLIGHTEDThe Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across 29 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed, via an outpatient endoscopy which applies a laser fiber illumination for 10 minutes in the proximity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care follow-up visits every three months with optional VTP therapy administered on each visit for up to 12 months. The study's primary objective is to assess the response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response. About ImPact BiotechImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: and the ENLIGHTED clinical trial website (for the US): Contacts Global Head of Business DevelopmentGuy Precision AQJohn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase (MTP) – – Interim analysis follows evaluation of 50% of target enrollment in study; completion of enrollment anticipated in 2H25 with topline data by year end – – Selected for late-breaking podium presentation today at 1:15 PM CT – TEL AVIV, Israel, May 31, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced updated interim results from ENLIGHTED, the Company's ongoing Phase 3 study of Padeliporfin VTP treatment in patients with low-grade upper tract urothelial cancer (UTUC). These data will be presented in a late-breaking podium session at the at the American Society of Clinical Oncology Annual Meeting taking place May 30 – June 3, 2025, in Chicago, Illinois. 'We are pleased to share this interim analysis, now capturing 50% of target enrollment in ENLIGHTED, which continues to reinforce Padeliporfin VTP's best-in-class potential in low-grade UTUC,' said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. 'We believe the emerging profile – a non-invasive treatment option delivering robust and sustained surgery-like efficacy, but without the associated risk of organ injury or loss – presents clear advantages over the standard of care. We are urgently progressing development to bring underserved UTUC patients this paradigm-shifting treatment and look forward to announcing potentially registrational topline data, including a view into durability, in UTUC within the year.' Key results from the interim analysis of the Phase 3 ENLIGHTED study of Padeliporfin VTP: As of November 5, 2024, the data cut-off for the poster presentation at ASCO, 43 patients had begun treatment, of which 37 had completed ITP and were evaluable for efficacy. Clinical Profile: 27 of the 37 (73%) response-evaluable patients achieved a CR at the end of ITP. 5 of the 37 (13.5%) response-evaluable patients achieved a partial response (PR) at the end of ITP. Safety and Tolerability Profile: Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the Phase 1 study and previously announced preliminary Phase 3 results. Adverse events (AEs): the majority of treatment-emergent adverse events (TEAEs) were mild or moderate and were primarily URS related, resolving within a few days. The most common Grade 3 serious adverse events related to VTP treatment were hematuria, dysuria and flank pain, which resolved within a few days. No TEAEs of special interest were reported and no TEAE led to discontinuation of the study treatment. ImPact continues to recruit for the ENLIGHTED study and expects to complete enrollment in the second half of 2025. The company anticipates the presentation of topline ENLIGHTED data in 2025. Podium Presentation Details: Poster Title: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC): ENLIGHTED phase 3 studyPresenter: Vitaly Margulis, Professor of Urologic Oncology, University of Texas Southwestern Medical CenterPoster Number: LBA4513Session Title: Bladder Cancer: Upper Tract Transitional Cell CarcinomaSession Date & Time: May 31, 2025, 1:15 PM CT About ENLIGHTEDThe Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across 29 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed, via an outpatient endoscopy which applies a laser fiber illumination for 10 minutes in the proximity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care follow-up visits every three months with optional VTP therapy administered on each visit for up to 12 months. The study's primary objective is to assess the response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response. About ImPact BiotechImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: and the ENLIGHTED clinical trial website (for the US): Contacts Global Head of Business DevelopmentGuy Precision AQJohn in to access your portfolio
Business Wire
3 days ago
- Business Wire
AtScale Advances Semantic Layer Leadership with Innovations for Generative AI and Open Source Standard at 2025 Summit
BOSTON--(BUSINESS WIRE)-- AtScale, the leading provider of semantic layer technology for analytics and AI, today unveiled new product innovations and open standards at the 2025 Semantic Layer Summit. The virtual event brought together over 5,000 data leaders to explore the future of governed, AI-ready analytics. This year's keynote, presented by AtScale Co-founder and CTO David Mariani, showcased the latest advancements in the company's Universal Semantic Layer Platform, including: GenAI Platform Integrations: Power trustworthy natural language analytics. AtScale now integrates natively with Databricks Genie and Snowflake Cortex Analyst, ensuring that AI-generated insights align with business definitions and governance policies. One-Click Modeling: Accelerate model creation with AI-powered automation. One-Click Modeling intelligently scans your source data to identify key metrics, dimensions, and relationships—eliminating manual configuration and reducing time to value. Composite Modeling: Enable decentralized collaboration without compromising consistency. Composite Modeling allows teams to extend or inherit existing models, making it easy to build on shared definitions while maintaining a single source of truth. Native PGWire Support: Seamlessly connect to modern BI tools. With inbound Postgres protocol support, AtScale now offers plug-and-play compatibility with ThoughtSpot, Superset, Sigma, and more—ensuring smooth integration across your analytics stack. Enhanced Power BI Integration: Deliver real-time insights with full governance. AtScale now supports native DAX and Tabular models in Power BI, enabling a unified semantic layer experience with live connectivity, consistent metrics, and no need for data duplication. In-Memory Aggregates: Achieve sub-second query performance. This new caching feature stores aggregated query results directly in memory, accelerating response times for even the most complex analytical workloads. 'AI and analytics are converging faster than ever—but without semantics, there's no foundation for trust,' said David Mariani, CTO and Co-founder of AtScale. 'The innovations we announced today reflect our mission to give every organization the power to scale insights securely, consistently, and intelligently. From model creation to AI integration, we're delivering a complete platform for the next era of data-driven business.' Driving Industry-Wide Standards Through Open Source A central theme of the 2025 summit was an open standard for semantic standardization to prevent semantic lock-in. AtScale officially introduced the Semantic Modeling Language (SML) —the industry's first open-source language designed for defining, sharing, and operationalizing semantic models. The SML GitHub repository now includes: Prebuilt semantic models for TPC-DS, AdventureWorks, and Snowplow datasets A developer SDK for reading and writing SML programmatically CLI tools for syntax validation, model deployment, and ecosystem translation Real-World Impact: Customers and Partners Take the Stage The summit featured real-world stories from AtScale customers who are transforming enterprise analytics with semantic layers: Home Depot showcased how AtScale's semantic layer on BigQuery enabled enterprise-wide self-service in Excel, reduced time-to-insight, and delivered sub-second performance on a 20TB cube—powering a trusted, governed foundation for natural language analytics. TELUS demonstrated how semantic layers enabled scalable telecom network analytics through vendor abstraction and SML adoption. Vodafone Portugal, in partnership with Celfocus, shared how they migrated legacy OLAP systems to a modern cloud-native stack on Google Cloud—preserving familiar BI workflows while boosting performance and governance. Blue Mercury and HSBC discussed best practices for semantic layer implementation, aligning technical and business teams around shared models and definitions. The Future of Semantics in the Age of AI The event closed with a forward-looking panel featuring leaders from Snowflake, IBM, Databricks, and ThoughtSpot, who discussed the growing role of semantic layers in powering GenAI and redefining modern BI. 'Semantic layers aren't just a trend—they're an essential foundation for trustworthy AI,' said Bruno Aziza, Group VP of Data, BI & AI at IBM. 'As enterprises scale GenAI, the semantic layer is what brings governance, consistency, and business context to every interaction.' With continued investments in openness, ecosystem integration, and AI innovation, AtScale is redefining what's possible with enterprise data. You can watch all of the 2025 Semantic Layer Sessions on-demand or read the event recap blog. About AtScale AtScale enables smarter decision-making by accelerating the flow of data-driven insights. The company's semantic layer platform simplifies, accelerates, and extends business intelligence and data science capabilities for enterprise customers across all industries. With AtScale, customers are empowered to democratize data, implement self-service BI, and build a more agile analytics infrastructure for better, more impactful decision-making. For more information, please visit and follow us on LinkedIn.
